AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.

Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33 in a deal of up to around $560m.

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.

As OEB6 increasingly appears in HPAPI and ADC manufacturing, the key question is whether pharmaceutical pipelines actually require a new exposure band — or whether the label is becoming commercial ...

From patient-centric designs and sustainable changes to component shortages, anti-counterfeiting, and low-volume production, sponsors of OSD products are navigating a number of packaging trends and ...

Despite Dr Heidi Overton’s declaration, senators questioned whether the commissioner-elect would challenge erroneous statements from president Trump.

Sandoz’s chief commercial officer discusses the company’s ambitious plans to have a biosimilar-driven growth engine by 2040.

The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics.

Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.

Biopharma firms are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China.

Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the fro ...

The cash will primarily fund Enveda’s continued development of three clinical-stage assets for inflammatory and metabolic disorders.